NCT05773937View on ClinicalTrials.gov

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

9MW2821

All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).

Trial Locations (2)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Beijing University Cancer Hospital, Beijing

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY